urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2025-13-5-106-115urovest-1150Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEМетодики повторной биопсии простаты и эффективность диагностики клинически значимого РПЖRepeat biopsy techniques and outcomes in the detection of clinically significant prostate cancerhttps://orcid.org/0000-0001-6322-7868ЖиловМ. С.ZhilovM. S.

Максим Сергеевич Жилов

Москва

Maksim S. Zhilov

Moscow

zhilovms@gmail.comhttps://orcid.org/0000-0002-2944-2668ГуспановР. И.GouspanovR. I.

Ренат Иватуллаевич Гуспанов – канд. мед. наук

Москва

Renat I. Guspanov – Cand.Sc.(Med)

Moscow

uroguspanov@yandex.ruhttps://orcid.org/0000-0001-8202-3844ЮсуфовА. Г.YusufovA. G.

Анвар Гаджиевич Юсуфов – канд. мед. наук

Москва

Anvar G. Yusufov – Сand.Sc.(Med)

Moscow

anvar.yusufov@mail.ruhttps://orcid.org/0000-0003-3764-6131КотовС. В.KotovS. V.

Сергей Владиславович Котов – д-р мед. наук, профессор

Москва

Sergey V. Kotov – Dr.Sc.(Med), Full Prof.

Moscow

urokotov@mail.ruРоссийский национальный исследовательский медицинский университет им Н. И. Пирогова, Московский многопрофильный клинический центр «Коммунарка»РоссияPirogov Russian National Research Medical University (Pirogov Medical University), «Kommunarka» Moscow Multidisciplinary Medical CentreRussian FederationРоссийский национальный исследовательский медицинский университет им Н. И. Пирогова, Московский многопрофильный клинический центр «Коммунарка», Городская клиническая больница № 1 им. Н. И. ПироговаРоссияPirogov Russian National Research Medical University (Pirogov Medical University), «Kommunarka» Moscow Multidisciplinary Medical Centre, Pirogov Moscow City Clinical Hospital No. 1Russian Federation202513012026136106115Copyright © Жилов М.С., Гуспанов Р.И., Юсуфов А.Г., Котов С.В., 20262026Жилов М.С., Гуспанов Р.И., Юсуфов А.Г., Котов С.В.Zhilov M.S., Gouspanov R.I., Yusufov A.G., Kotov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/1150Введение

Введение. Биопсия является стандартом верификации злокачественного новообразования простаты. Отрицательная первичная биопсия простаты не исключает отсутствие у пациента рака предстательной железы (РПЖ) при дальнейшем наблюдении. В настоящем обзоре рассмотрены различные методики выполнения повторной биопсии и результаты эффективности диагностики клинически значимого РПЖ.

Цель исследования

Цель исследования. Изучить различные методики повторной биопсии простаты и оценить эффективность диагностики клинически значимого РПЖ.

Материалы и методы

Материалы и методы. Проведён обзор электронных баз данных PubMed, eLibrary с 2000 по 2024 год, чтобы выявить все соответствующие исследования. Электронный поиск был ограничен русским и английским языком, использовали ключевые слова: «повторная биопсия простаты», «клинически значимый рак предстательной железы», «fusion-биопсия».

Результаты

Результаты. В настоящее время для выполнения повторной биопсии предстательной железы возможно использование следующих техник: сатурационная биопсия, микро-УЗИ, гистосканирование и fusion-биопсия. Сатурационная биопсия сопряжена с увеличением количества осложнений, гистосканирование не показало высокой эффективности, микро-УЗИ не так распространено и ограничено количеством исследований. Преимущество диагностики клинически значимого РПЖ у пациентов с предыдущим отрицательным гистологическим заключением на сегодняшний день за fusion-биопсией. Особенностью является возможность выбора одной из трёх техник выполнения: аппаратная, когнитивная и in bore.

Заключение

Заключение. Наилучшие результаты эффективности диагностики клинически значимых форм РПЖ при повторной биопсии показывает fusion-техника. По данным литературы, различные способы выполнения fusion-биопсии сопоставимы между собой.

 

 

Introduction

Introduction. Prostate biopsy remains the definitive standard for confirming malignancy in the prostate. However, a negative initial biopsy does not rule out the presence of prostate cancer (PCa) during subsequent follow-up. This review provides an overview of current repeat biopsy techniques and assesses their diagnostic accuracy for clinically significant PCa (csPCa).

Objective

Objective. To study various methods of repeated biopsy and evaluate the results of diagnosis of csPCa.

Materials & Methods

Materials & Methods. A review of PubMed, eLibrary electronic databases was conducted from 2000 to 2024 to identify all relevant studies. The electronic search was limited to Russian and English, and the keywords used were: repeat prostate biopsy, clinically significant prostate cancer, fusion biopsy.

Results

Results. Currently, the following techniques can be used to perform a repeat prostate biopsy: saturation biopsy, micro-ultrasound, histoscanning and fusion biopsy. Saturation biopsy is associated with an increase in the number of complications, histoscanning has not shown high efficiency, micro-ultrasound is not so common and is limited by the number of studies. The advantage of diagnosing csPCa in patients with a previous negative histological conclusion is currently behind fusion biopsy. One of the advantages is the ability to choose one of three execution techniques: fusion, cognitive and in bore.

Conclusions

Conclusions. Fusion technique shows the best results of the effectiveness of the diagnosis of csPCa with repeated biopsy. According to the literature, various methods of performing fusion biopsies are comparable to each other.

повторная биопсия предстательной железысатурационная биопсиягистосканинграк предстательной железыприцельная биопсияfusion-биопсияrepeated prostate biopsysaturation biopsyhistoscanningprostate cancertargeted biopsyfusion biopsyReferencesSiegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. DOI: 10.3322/caac.21708Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. DOI: 10.3322/caac.21708Scattoni V., Zlotta A., Montironi R., Schulman C., Rigatti P., Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007;52(5):1309-1322. DOI: 10.1016/j.eururo.2007.08.006Scattoni V., Zlotta A., Montironi R., Schulman C., Rigatti P., Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007;52(5):1309-1322. DOI: 10.1016/j.eururo.2007.08.006Welch H.G., Fisher E.S., Gottlieb D.J., Barry M.J. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007;99(18):1395-1400. DOI: 10.1093/jnci/djm119Welch H.G., Fisher E.S., Gottlieb D.J., Barry M.J. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007;99(18):1395-1400. DOI: 10.1093/jnci/djm119Djavan B., Ravery V., Zlotta A., Dobronski P., Dobrovits M., Fakhari M., Seitz C., Susani M., Borkowski A., Boccon-Gibod L., Schulman C.C., Marberger M. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166(5):1679-1683. PMID: 11586201Djavan B., Ravery V., Zlotta A., Dobronski P., Dobrovits M., Fakhari M., Seitz C., Susani M., Borkowski A., Boccon-Gibod L., Schulman C.C., Marberger M. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166(5):1679-1683. PMID: 11586201Nafie S., Wanis M., Khan M. The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy. Urol J. 2017;14(2):3008-3012. PMID: 28299763Nafie S., Wanis M., Khan M. The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy. Urol J. 2017;14(2):3008-3012. PMID: 28299763Scattoni V., Raber M., Capitanio U., Abdollah F., Roscigno M., Angiolilli D., Maccagnano C., Gallina A., Saccà A., Freschi M., Doglioni C., Rigatti P., Montorsi F.. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60(4):834-841. DOI: 10.1016/j.eururo.2011.07.036Scattoni V., Raber M., Capitanio U., Abdollah F., Roscigno M., Angiolilli D., Maccagnano C., Gallina A., Saccà A., Freschi M., Doglioni C., Rigatti P., Montorsi F.. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60(4):834-841. DOI: 10.1016/j.eururo.2011.07.036Stewart C.S., Leibovich B.C., Weaver A.L., Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166(1):86-91; discussion 91-92. PMID: 11435830Stewart C.S., Leibovich B.C., Weaver A.L., Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166(1):86-91; discussion 91-92. PMID: 11435830Кельн А.А., Зырянов А.В., Зотов П.Б., Пономарев А.В., Суриков А.С., Знобищев В.Г. Роль сатурационной трансперинеальной биопсии в диагностике рака предстательной железы в «эру» таргетной fusion- биопсии. Креативная хирургия и онкология. 2018;8(2):111-116.Keln A.A., Zyryanov A.V., Zotov P.V., Ponomarev A.V., Surikov A.S., Znobischev V.G. The Role of Saturation Transperineal Biopsy in the Diagnosis of Prostate Cancer in the Era of Targeted Fusion Biopsies. Creative surgery and oncology. 2018;8(2):111-116. (In Russian). DOI: 10.24060/2076-3093-2018-8-2-27-32Abdollah F., Novara G., Briganti A., Scattoni V., Raber M., Roscigno M., Suardi N., Gallina A., Artibani W., Ficarra V., Cestari A., Guazzoni G., Rigatti P., Montorsi F. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011;77(4):921-925. DOI: 10.1016/j.urology.2010.08.048Abdollah F., Novara G., Briganti A., Scattoni V., Raber M., Roscigno M., Suardi N., Gallina A., Artibani W., Ficarra V., Cestari A., Guazzoni G., Rigatti P., Montorsi F. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011;77(4):921-925. DOI: 10.1016/j.urology.2010.08.048Watanabe M., Hayashi T., Tsushima T., Irie S., Kaneshige T., Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. Int J Urol. 2005;12(11):959-963. DOI: 10.1111/j.1442-2042.2005.01186.xWatanabe M., Hayashi T., Tsushima T., Irie S., Kaneshige T., Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. Int J Urol. 2005;12(11):959-963. DOI: 10.1111/j.1442-2042.2005.01186.xDelongchamps N.B., de la Roza G., Jones R., Jumbelic M., Haas G.P. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 2009;103(1):49-54. DOI: 10.1111/j.1464-410X.2008.07900.xDelongchamps N.B., de la Roza G., Jones R., Jumbelic M., Haas G.P. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 2009;103(1):49-54. DOI: 10.1111/j.1464-410X.2008.07900.xBraeckman J., Autier P., Garbar C., Marichal M.P., Soviany C., Nir R., Nir D., Michielsen D., Bleiberg H., Egevad L., Emberton M. Computeraided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008;101(3):293-298. DOI: 10.1111/j.1464-410X.2007.07232.xBraeckman J., Autier P., Garbar C., Marichal M.P., Soviany C., Nir R., Nir D., Michielsen D., Bleiberg H., Egevad L., Emberton M. Computeraided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008;101(3):293-298. DOI: 10.1111/j.1464-410X.2007.07232.xGlybochko P.V., Alyaev Y.G., Amosov A.V., Krupinov G.E., Nir D., Winkler M., Ganzha T.M.. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice. Eur Urol Focus. 2019;5(2):179-185. DOI: 10.1016/j.euf.2017.07.001Glybochko P.V., Alyaev Y.G., Amosov A.V., Krupinov G.E., Nir D., Winkler M., Ganzha T.M.. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice. Eur Urol Focus. 2019;5(2):179-185. DOI: 10.1016/j.euf.2017.07.001Vezelis Alvydas A., Platkevicius G., Kincius K.M., Naruseviciute I., Ulys A., Jankevicius F. Prostate 3D ultrasound-guided imaging device (Histo- Scanning) performance detecting clinically significant prostate cancer. J BUON. 2020;25(1):460-463. PMID: 32277669Vezelis Alvydas A., Platkevicius G., Kincius K.M., Naruseviciute I., Ulys A., Jankevicius F. Prostate 3D ultrasound-guided imaging device (Histo- Scanning) performance detecting clinically significant prostate cancer. J BUON. 2020;25(1):460-463. PMID: 32277669Morozov A., Kozlov V., Rivas J.G., Teoh J.Y., Bezrukov E., Amosov A., Barret E., Taratkin M., Salomon G., Herrmann T.R.W., Gozen A., Enikeev D.; collaboration between ESUT, ESUI and Uro-technology WP of the Young Academic Urologists. A systematic review and meta-analysis of Histoscanning™ in prostate cancer diagnostics. World J Urol. 2021;39(10):3733-3740. DOI: 10.1007/s00345-021-03684-8Morozov A., Kozlov V., Rivas J.G., Teoh J.Y., Bezrukov E., Amosov A., Barret E., Taratkin M., Salomon G., Herrmann T.R.W., Gozen A., Enikeev D.; collaboration between ESUT, ESUI and Uro-technology WP of the Young Academic Urologists. A systematic review and meta-analysis of Histoscanning™ in prostate cancer diagnostics. World J Urol. 2021;39(10):3733-3740. DOI: 10.1007/s00345-021-03684-8Hamann M.F., Hamann C., Trettel A., Jünemann K.P., Naumann C.M. Computer-aided transrectal ultrasound: does prostate HistoScanning™ improve detection performance of prostate cancer in repeat biopsies? BMC Urol. 2015;15:76. DOI: 10.1186/s12894-015-0072-zHamann M.F., Hamann C., Trettel A., Jünemann K.P., Naumann C.M. Computer-aided transrectal ultrasound: does prostate HistoScanning™ improve detection performance of prostate cancer in repeat biopsies? BMC Urol. 2015;15:76. DOI: 10.1186/s12894-015-0072-zКотов С.В., Гуспанов Р.И., Пульбере С.А., Юсуфов А.Г., Хачатрян А.Л., Бядретдинов И.Ш., Жилов М.С., Алекберов Э.М., Логвинова С.Л. Результаты использования аппарата HistoScanningTM для диагностики рака предстательной железы в сравнении со стандартной мультифокальной биопсией. Вестник урологии. 2023;11(4):62-71.Kotov S.V., Guspanov R.I., Pulbere S.A., Yusufov A.G., Khachatryan A.L., Badretdinov I.S., Zhilov M.S., Alekberov E.M., Logvinova S.L. HistoScanningTM vs. standard multifocal biopsy for prostate cancer diagnosis: a comparison of diagnostic methods. Urology Herald. 2023;11(4):62-71. (In Russian). DOI: 10.21886/2308-6424-2023-11-4-62-71Glybochko P.V., Alyaev YG, Amosov A.V., Krupinov G.E., Nir D., Winkler M., et al. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice. Eur Urol Focus 2019;5:179-85. DOI: 10.1016/j.euf.2017.07.001.Glybochko P.V., Alyaev YG, Amosov A.V., Krupinov G.E., Nir D., Winkler M., et al. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice. Eur Urol Focus 2019;5:179-85. DOI: 10.1016/j.euf.2017.07.001.Javed S., Chadwick E., Edwards A.A., Beveridge S., Laing R., Bott S., Eden C., Langley S. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int. 2014;114(4):541-548. DOI: 10.1111/bju.12568Javed S., Chadwick E., Edwards A.A., Beveridge S., Laing R., Bott S., Eden C., Langley S. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int. 2014;114(4):541-548. DOI: 10.1111/bju.12568Rohrbach D., Wodlinger B., Wen J., Mamou J., Feleppa E. High-Frequency Quantitative Ultrasound for Imaging Prostate Cancer Using a Novel Micro-Ultrasound Scanner. Ultrasound Med Biol. 2018;44(7):1341-1354. DOI: 10.1016/j.ultrasmedbio.2018.02.014Rohrbach D., Wodlinger B., Wen J., Mamou J., Feleppa E. High-Frequency Quantitative Ultrasound for Imaging Prostate Cancer Using a Novel Micro-Ultrasound Scanner. Ultrasound Med Biol. 2018;44(7):1341-1354. DOI: 10.1016/j.ultrasmedbio.2018.02.014Turkbey B., Choyke P.L. PIRADS 2.0: what is new? Diagn Interv Radiol. 2015;21(5):382-384. DOI: 10.5152/dir.2015.15099Turkbey B., Choyke P.L. PIRADS 2.0: what is new? Diagn Interv Radiol. 2015;21(5):382-384. DOI: 10.5152/dir.2015.15099Klotz L., Lughezzani G., Maffei D., Sánchez A., Pereira J.G., Staerman F., Cash H., Luger F., Lopez L., Sanchez-Salas R., Abouassaly R., Shore N.D., Eure G., Paciotti M., Astobieta A., Wiemer L., Hofbauer S., Heckmann R., Gusenleitner A., Kaar J., Mayr C., Loidl W., Rouffilange J., Gaston R., Cathelineau X., Klein E. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Can Urol Assoc J. 2021;15(1):E11-E16. Erratum in: Can Urol Assoc J. 2022;16(2):E111. DOI: 10.5489/cuaj.6712Klotz L., Lughezzani G., Maffei D., Sánchez A., Pereira J.G., Staerman F., Cash H., Luger F., Lopez L., Sanchez-Salas R., Abouassaly R., Shore N.D., Eure G., Paciotti M., Astobieta A., Wiemer L., Hofbauer S., Heckmann R., Gusenleitner A., Kaar J., Mayr C., Loidl W., Rouffilange J., Gaston R., Cathelineau X., Klein E. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Can Urol Assoc J. 2021;15(1):E11-E16. Erratum in: Can Urol Assoc J. 2022;16(2):E111. DOI: 10.5489/cuaj.6712Lian H., Zhuang J., Wang W., Zhang B., Shi J., Li D., Fu Y., Jiang X., Zhou W, Guo H. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen. BMC Urol. 2017;17(1):52. DOI: 10.1186/s12894-017-0241-3Lian H., Zhuang J., Wang W., Zhang B., Shi J., Li D., Fu Y., Jiang X., Zhou W, Guo H. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen. BMC Urol. 2017;17(1):52. DOI: 10.1186/s12894-017-0241-3Глыбочко П.В., Аляев Ю.Г., Амосов А.В., Еникеев Д.В., Чинёнов Д.В., Крупинов Г.Е., Пузаков К.Б., Кошкарев А.В., Лернер Ю.В., Петровский Н.В., Джалаев З.К., Чернов Я.Н. МпМРТ/УЗИ fusion-биопсия в диагностике рака предстательной железы. Наш опыт. Урология. 2018;(3):98-104.Glybochko P.V., Alyaev Yu.G., Amosov A.V., Enikeev D.V., Chinenov D.V., Krupinov G.E., Puzakov K.B., Koshkarev A.V., Lerner Yu.V., Petrovskii N.V., Dzhalaev Z.K., Chernov Ya.N. Multi-parametric MRI/US fusion guided biopsy for the diagnosis of prostate cancer. our experience. Urologiia. 2018;(3):98-104. (In Russian). DOI: 10.18565/urology.2018.3.98-104Зырянов А.В., Кельн А.А., Суриков А.С., Пономарев А.В., Купчин А.В., Лебедев А.В., Попов И.Б. Диагностическая ценность повторной биопсии предстательной железы под fusion-контролем. Онкоурология. 2017;13(3):71-75.Zyryanov A.V., Keln A.A., Surikov A.S., Ponomarev A.V., Kupchin A.V., Lebedev A.V., Popov I.B. The prognostic value of repeated prostate fusion biopsy. Cancer Urology. 2017;13(3):71-75. (In Russian). DOI: 10.17650/1726-9776-2017-13-3-71-75Hwang S.I., Lee H.J., Lee S.E., Hong S.K., Byun S.S., Lee S.C., Choe G. Value of MR-US fusion in guidance of repeated prostate biopsy in men with PSA < 10 ng/mL. Clin Imaging. 2019;53:1-5. DOI: 10.1016/j.clinimag.2018.09.012Hwang S.I., Lee H.J., Lee S.E., Hong S.K., Byun S.S., Lee S.C., Choe G. Value of MR-US fusion in guidance of repeated prostate biopsy in men with PSA < 10 ng/mL. Clin Imaging. 2019;53:1-5. DOI: 10.1016/j.clinimag.2018.09.012Borkowetz A., Platzek I., Toma M., Laniado M., Baretton G., Froehner M., Koch R., Wirth M., Zastrow S. Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate cancer. BJU Int. 2015;116(6):873-879. DOI: 10.1111/bju.13023Borkowetz A., Platzek I., Toma M., Laniado M., Baretton G., Froehner M., Koch R., Wirth M., Zastrow S. Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate cancer. BJU Int. 2015;116(6):873-879. DOI: 10.1111/bju.13023Meng X., Rosenkrantz A.B., Mendhiratta N., Fenstermaker M., Huang R., Wysock J.S., Bjurlin M.A., Marshall S., Deng F.M., Zhou M., Melamed J., Huang W.C., Lepor H., Taneja S.S. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512-517. DOI: 10.1016/j.eururo.2015.06.005Meng X., Rosenkrantz A.B., Mendhiratta N., Fenstermaker M., Huang R., Wysock J.S., Bjurlin M.A., Marshall S., Deng F.M., Zhou M., Melamed J., Huang W.C., Lepor H., Taneja S.S. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512-517. DOI: 10.1016/j.eururo.2015.06.005Salami S.S., Ben-Levi E., Yaskiv O., Ryniker L., Turkbey B., Kavoussi L.R., Villani R., Rastinehad A.R. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? BJU Int. 2015;115(4):562-570. DOI: 10.1111/bju.12938Salami S.S., Ben-Levi E., Yaskiv O., Ryniker L., Turkbey B., Kavoussi L.R., Villani R., Rastinehad A.R. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? BJU Int. 2015;115(4):562-570. DOI: 10.1111/bju.12938Häggman M., Dahlman P., Ahlberg M., Liss P., Cantera Ahlman R., Dragomir A., Ladjevardi S. Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors. Acta Radiol Open. 2022;11(3):20584601221085520. DOI: 10.1177/20584601221085520Häggman M., Dahlman P., Ahlberg M., Liss P., Cantera Ahlman R., Dragomir A., Ladjevardi S. Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors. Acta Radiol Open. 2022;11(3):20584601221085520. DOI: 10.1177/20584601221085520Murphy I.G., NiMhurchu E., Gibney R.G., McMahon C.J. MRI-directed cognitive fusion-guided biopsy of the anterior prostate tumors. Diagn Interv Radiol. 2017;23(2):87-93. DOI: 10.5152/dir.2016.15445Murphy I.G., NiMhurchu E., Gibney R.G., McMahon C.J. MRI-directed cognitive fusion-guided biopsy of the anterior prostate tumors. Diagn Interv Radiol. 2017;23(2):87-93. DOI: 10.5152/dir.2016.15445Kuliš T., Zekulić T., Alduk A.M., Lušić M., Bulimbašić S., Ferenčak V., Mokos I., Hudolin T., Kaštelan Ž. Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam. Croat Med J. 2020;61(1):49-54. DOI: 10.3325/cmj.2020.61.49Kuliš T., Zekulić T., Alduk A.M., Lušić M., Bulimbašić S., Ferenčak V., Mokos I., Hudolin T., Kaštelan Ž. Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam. Croat Med J. 2020;61(1):49-54. DOI: 10.3325/cmj.2020.61.49Penzkofer T., Tempany-Afdhal C.M. Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist’s perspective. NMR Biomed. 2014;27(1):3-15. DOI: 10.1002/nbm.3002Penzkofer T., Tempany-Afdhal C.M. Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist’s perspective. NMR Biomed. 2014;27(1):3-15. DOI: 10.1002/nbm.3002Schaudinn A., Busse H., Ehrengut C., Linder N., Ludwig J., Franz T., Horn L.C., Stolzenburg J.U., Denecke T. Prostate cancer detection with transrectal in-bore MRI biopsies: impact of prostate volume and lesion features. Insights Imaging. 2025;16(1):69. DOI: 10.1186/s13244-025-01942-6Schaudinn A., Busse H., Ehrengut C., Linder N., Ludwig J., Franz T., Horn L.C., Stolzenburg J.U., Denecke T. Prostate cancer detection with transrectal in-bore MRI biopsies: impact of prostate volume and lesion features. Insights Imaging. 2025;16(1):69. DOI: 10.1186/s13244-025-01942-6Venderink W., Jenniskens S.F., Michiel Sedelaar J.P., Tamada T., Fütterer J.J. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB. Korean J Radiol. 2018;19(4):733-741. DOI: 10.3348/kjr.2018.19.4.733Venderink W., Jenniskens S.F., Michiel Sedelaar J.P., Tamada T., Fütterer J.J. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB. Korean J Radiol. 2018;19(4):733-741. DOI: 10.3348/kjr.2018.19.4.733Hosseiny M., Shakeri S., Felker E.R., Lu D., Sayre J., Ahuja P., Raman S.S. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy. AJR Am J Roentgenol. 2020;215(3):660-666. DOI: 10.2214/AJR.19.22455Hosseiny M., Shakeri S., Felker E.R., Lu D., Sayre J., Ahuja P., Raman S.S. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy. AJR Am J Roentgenol. 2020;215(3):660-666. DOI: 10.2214/AJR.19.22455D’Agostino D., Romagnoli D., Giampaoli M., Bianchi F.M., Corsi P., Del Rosso A., Schiavina R., Brunocilla E., Artibani W., Porreca A. “In-Bore” MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. Curr Urol. 2020;14(1):22-31. DOI: 10.1159/000499264D’Agostino D., Romagnoli D., Giampaoli M., Bianchi F.M., Corsi P., Del Rosso A., Schiavina R., Brunocilla E., Artibani W., Porreca A. “In-Bore” MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. Curr Urol. 2020;14(1):22-31. DOI: 10.1159/000499264Wegelin O., Exterkate L., van der Leest M., Kummer J.A., Vreuls W., de Bruin P.C., Bosch J.L.H.R., Barentsz J.O., Somford D.M., van Melick H.H.E. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. DOI: 10.1016/j.eururo.2018.11.040Wegelin O., Exterkate L., van der Leest M., Kummer J.A., Vreuls W., de Bruin P.C., Bosch J.L.H.R., Barentsz J.O., Somford D.M., van Melick H.H.E. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. DOI: 10.1016/j.eururo.2018.11.040

The authors declare that there are no conflicts of interest present.